Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Generic Drugs

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1280548

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1280548

Generic Drugs

PUBLISHED:
PAGES: 711 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5450
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16350

Add to Cart

Description

Table of Contents

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Generic Drugs Market to Reach $671.5 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Generic Drugs estimated at US$403.9 Billion in the year 2022, is projected to reach a revised size of US$671.5 Billion by 2030, growing at aCAGR of 6.6% over the period 2022-2030. Small-Molecule Generics, one of the segments analyzed in the report, is projected to record 4.8% CAGR and reach US$538.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Biosimilars segment is readjusted to a revised 19.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $122.8 Billion, While China is Forecast to Grow at 8.2% CAGR

The Generic Drugs market in the U.S. is estimated at US$122.8 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$126.8 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 5.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Select Competitors (Total 255 Featured) -

  • Astellas Pharma, Inc.
  • Biocon Ltd.
  • 3SBio, Inc.
  • Arbor Pharmaceuticals LLC
  • AristoPharma Ltd.
  • Breckenridge Pharmaceutical, Inc.
  • Amphastar Pharmaceuticals, Inc.
  • Advance Pharmaceutical Inc.
  • Celltrion, Inc.
  • Acadia Pharmaceuticals, Inc.
  • Acino International AG
  • Acella pharmaceuticals
  • Argentum Pharmaceuticals
  • AustarPharma, LLC
  • API Pharma Tech
Show more
Product Code: MCP12162

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of Covid-19 and Global Economic Update
    • From Pandemic to War & Inflation: "Gloomy Outlook for 2023 Despite Signs of Easing Inflationary Conditions
    • Here's How Inflationary Pressures Affect the Economy
    • Russia-Ukraine War, the Primary Culprit Responsible for the Hardships
    • Although Past Peak in 2023, Efforts to Solve the Inflation Puzzle Should Continue
    • Here's What's Causing Inflationary Pressures in the Global Market
    • Shaken by the War, Global Oil Prices Spiral and Feed Inflationary Pressures, Guiding the World Towards a Cost of Living Crisis: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2017 through 2024
    • War-Induced Commodity Price Increases & Broad Based Price Pressures Mark the Return of Global Inflation to the Highest Level Seen Since 1996: Global Inflation Rates (In %) for the Years 2019 Through 2024
    • Although Facing a Lower Recession Risk, Global Economic Growth in 2023 to Slowdown Amid War, Inflation, Elevated Interest Rates & Marginal Easing of Inflation: World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2020 Through 2024
    • Recession Triggered by Uncontrolled Inflation or Unemployment, Which is the Greater Evil? Inflation Battling Policy Measures to Slowdown Post Pandemic Recovery in Unemployment Rates: Global Number of Unemployed People (In Million) for Years 2019 Through 2024
    • How the Healthcare Industry Has Been Impacted by the Pandemic & What's the New Normal?
    • With the COVID-19 Pandemic Exposing Global Healthcare Unpreparedness, There is Increasing Policy Led Focus on Rebooting Health Systems Worldwide: Current & Required Healthcare Spending as % of GDP
    • COVID-19 Impact on Global Pharmaceutical Supply Chain and Generic Drugs Market
    • Demand for Generic Pain Killers Rises
    • A Prelude to Generic Drugs
    • Generic Drugs Market Set for a Rapid Growth
    • North America and Europe Dominate, Asia-Pacific to Exhibit the Fastest Growth
    • India- A Significant Market
    • Small-molecule Generic Drugs Account for a Lion's Share, Biosimilars Exhibit Fastest Growth
    • Exciting Times for Biosimilars
    • Competition
    • Generic Drugs - Global Key Competitors Percentage Market Share in 2023 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
    • Market Opportunities
    • Strategies to Sustain Success
    • The Future of Generics & Biosimilars Look Bright amid Persistent Barriers
    • Market Challenges
    • Factors Affecting Prices & Accessibility
    • Recent Market Activity
  • BRANDS
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Generic Drugs Enjoy Adrenaline Rush with Regulatory & Scientific Support
    • R&D & Innovation Push
    • Efforts to Eliminate Barriers to Generics Development
    • Regulatory & Scientific Collaboration as Key
    • FDA's Generic Drug User Free Program
    • Policy Support to Generic Drugs: Clearing Road to Affordable Access to Quality Medicines
    • Savings in Billions
    • Taking GDUFA to Next Level
    • Pushing Competition through ANDAs
    • Major Push to COVID-19 Drugs
    • Patent Expiries Set to Widen the Addressable Market for Generic Drugs
    • Patent Expiries of Select Drugs in 2020
    • Patent Expiries of Select Drugs in 2021
    • Patent Expiries of Select Drugs in 2022
    • Patent Expiries of Select Drugs in 2023
    • Patent Expiry of Select Major Drugs in the US: 2020-2023
    • Robust Demand for Pharmaceutical Drugs Drives Demand for Generic Drugs
    • Cost Containment Measures Put Focus on Generics
    • Small Molecule Generics Represent the Dominant Segment
    • Specialty Generic Drugs Gain Popularity
    • Specialty Generics - The Way to Success Amid Challenges
    • Factors that can Provide Competitive Edge
    • Increasing Demand for Biosimilars, Driven by Patent Expiry of Major Biopharmaceutical Drugs
    • Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe in the Recent Past
    • Progressive Regulatory Framework Accelerates Product Approvals & Subsequently Market Revenues
    • Specific Guidelines for Biosimilars in Various Countries with Year of Publication
    • Biosimilars Regulatory Agencies in Select Regional Markets
    • Biosimilar Approvals in the US (as of 2023)
    • Biosimilar Approvals in Europe (as of 2023)
    • Rising Healthcare Costs Drive Demand for Generic Drugs
    • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Aging Population to Propel the Demand for Generic Drugs
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Significant Increase in Number of Patients Suffering from Chronic Diseases Fuel Demand for Generic Medicines
    • Global Cost of Chronic Diseases (In US$ Billion) for the Years 2018 and 2030
    • Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Number of New Cancer Cases and Deaths (in Million) by Region for 2018
    • US Regulators Struggle to Keep Up with the Global Market
    • Increased Dependency on Non-US Manufacturers
    • Patient Trust and Traceability
    • Drug Supply Shortage Risks
    • Fixing a Broken System
    • Hospitals Teaming Up to Develop Own Generic Drugs to Combat Shortages and High Prices
    • Use of Artificial Intelligence and Machine Learning in Pharmaceutical Manufacturing Witnesses a Surge
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Generic Drugs Market Analysis of Annual Sales in US$ Million for Years 2018 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 4: World 12-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2018, 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Small-Molecule Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Small-Molecule Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 7: World 12-Year Perspective for Small-Molecule Generics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2023 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 10: World 12-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2023 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 13: World 12-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2023 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 16: World 12-Year Perspective for Central Nervous System (CNS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2023 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Dermatology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Dermatology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 19: World 12-Year Perspective for Dermatology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2023 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 22: World 12-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2023 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 25: World 12-Year Perspective for Respiratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2023 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Therapeutic Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Therapeutic Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 28: World 12-Year Perspective for Other Therapeutic Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2023 & 2030
    • A Prelude to Generic Drugs

III. MARKET ANALYSIS

  • UNITED STATES
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 31: USA 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 34: USA 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • CANADA
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Canada for 2023 (E)
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 37: Canada 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 40: Canada 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • JAPAN
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 43: Japan 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 46: Japan 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • CHINA
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 49: China 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 52: China 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • EUROPE
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Generic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 55: Europe 12-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2018, 2023 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 58: Europe 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 61: Europe 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • FRANCE
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 64: France 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 67: France 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • GERMANY
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 70: Germany 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 73: Germany 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 76: Italy 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 79: Italy 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • UNITED KINGDOM
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 82: UK 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 85: UK 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 88: Spain 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 91: Spain 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 94: Russia 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 97: Russia 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 100: Rest of Europe 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 103: Rest of Europe 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • ASIA-PACIFIC
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Generic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 106: Asia-Pacific 12-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2018, 2023 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 109: Asia-Pacific 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 112: Asia-Pacific 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • AUSTRALIA
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 115: Australia 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 118: Australia 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • INDIA
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 121: India 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 124: India 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 127: South Korea 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 130: South Korea 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • LATIN AMERICA
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Generic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 139: Latin America 12-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2018, 2023 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 142: Latin America 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 145: Latin America 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 148: Argentina 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 151: Argentina 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 154: Brazil 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 157: Brazil 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 160: Mexico 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 163: Mexico 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 166: Rest of Latin America 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 169: Rest of Latin America 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • MIDDLE EAST
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Generic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 172: Middle East 12-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2018, 2023 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 175: Middle East 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 178: Middle East 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 181: Iran 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 184: Iran 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 187: Israel 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 190: Israel 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 193: Saudi Arabia 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 196: Saudi Arabia 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 199: UAE 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 202: UAE 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 205: Rest of Middle East 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 208: Rest of Middle East 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030
  • AFRICA
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 211: Africa 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2023 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2021 and % CAGR
    • TABLE 214: Africa 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2023 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!